600
BACKGROUND: To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.
 chronic hepatitis C patients: Subject; retinopathy: Effect; pegylated interferon and ribavirin combination therapy: Treatment; ribavirin: Treatment.Drug; pegylated interferon: Treatment.Drug; chronic hepatitis C: Treatment.Disorder; ribavirin: Combination.Drug; pegylated interferon: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 chronic hepatitis C patients: Subject; retinopathy: Effect; pegylated interferon and ribavirin combination therapy: Treatment; ribavirin: Treatment.Drug; pegylated interferon: Treatment.Drug; chronic hepatitis C: Treatment.Disorder; ribavirin: Combination.Drug; pegylated interferon: Combination.Drug